Caspases are key enzymes responsible for mediating apoptotic cell death. Across species, caspase-2 is the most conserved caspase and stands out due to unique features.
Introduction
Normal development and tissue homeostasis are regulated by apoptosis, a form of Programmed Cell Death (PCD) defined by unique morphological and biochemical features [1] . Caspases are key executioner enzymes of apoptosis and depending on the chronology of activation, they are classified into initiator and effector caspases [2] .
Caspases cleave hundreds of substrates to elicit an apoptotic phenotype and thus the activation of caspases is tightly controlled. Inhibitor of Apoptosis proteins (IAPs) are thus far the only known endogenous inhibitors of caspases as they can directly bind to caspases and prevent their activation [3] . Initiator caspases are activated by dimerization, which is accomplished by recruitment of caspase monomers to multimeric protein complexes assembled in cells in response to apoptotic stimuli [4] . For instance, caspase-8 is recruited and activated in the Death Inducing Signaling Complex (DISC) and caspase-9 is recruited to the apoptosome for activation [5] . Caspase-2 is a unique member of the caspase family as it exhibits features of both initiator and effector caspases [6] . More recent studies revealed other functions of this caspase: it supresses tumours, plays a role in autophagy and regulates metabolism and aging (for reviews see [7, 8] ). In response to DNA damage, caspase-2 is recruited to a high molecular weight complex called PIDDosome which contains PIDD (p53-induced protein with a death domain DD) and the adapter protein RAIDD (receptor-interacting protein-associated ICH-1/CED-3 homologous protein with a DD) [9] . However, recent evidence suggests that caspase-2 can be activated in a PIDDosome-independent manner [10] . We have previously shown that caspase-2 functions as an initiator caspase during pore forming toxin (PFT)-mediated apoptosis in a variety of cell types [11] . In these settings, the activation of caspase-2 is PIDDosome-independent and critically dependent on the intracellular potassium ion concentration. Depletion of intracellular potassium ions by PFTs led to oligomerization and recruitment of caspase-2 into a high molecular weight complex thus leading to its activation.
In our attempts to uncover the molecular determinants that drive the activation dynamics of caspase-2 in PFT-mediated apoptosis, we identified API5/AAC-11/FIF (Anti-apoptosis clone 11 and Fibroblast growth factor-2 interacting factor) as a novel inhibitor of caspase-2. API5 was originally discovered as a protein responsible for protecting cells against growth factor deprivation-induced cell death [12] . API5 can also bind to acinus, ALC1 and FGF2 regulating cell death and tumorigenesis [13] [14] [15] [16] .
Structurally, API5 comprises of multiple helices constituting HEAT (Huntington, Elongation Factor 3, PR65/A, TOR)-like and ARM (Armadillo)-like repeats that mediate protein-protein interactions [17] . API5 also inhibits E2F1-dependent apoptosis in a transcription-independent manner [18] . Recent studies revealed that API5 is highly expressed in various cancers and associated with poor prognosis especially in NSCLCs and cervical cancer, however, the molecular mechanisms behind API5-mediated cell survival remains poorly understood [19, 20] . Here, we reveal that API5 directly binds to the CARD domain of caspase-2 and prevents its dimerization and activation. Loss of API5 thus sensitizes cells to caspase-2 dependent apoptotic cell death.
Results and discussion
Caspase-2 functions as an initiator caspase during PFT-mediated apoptosis in multiple cell types [11] . To identify proteins that regulate caspase-2 activation in these settings, we have performed a mass spectrometry-based analysis of active caspase-2-containing protein complexes. HeLa cells treated with biotin-VAD-fmk were subjected to α-toxin treatment and proteins bound to biotin-VAD-fmk were precipitated by streptavidin beads. We subjected the proteins bound to the streptavidin beads to trypsin digestion and performed mass spectrometry analysis. As expected, caspase-2 peptides were identified and among the other co-precipitated proteins, we identified four unique peptides with six peptide spectrum matches for Apoptosis Inhibitor 5 (Fig. 1a) . We confirmed the presence of API5 in active caspase-2-containing complexes by immunoblots (Fig. 1b) . As shown before [14, 19] , API5 antibodies detect a double band in HeLa cells recognising both the 55 and 57 KDa isoforms (Fig.1b) . Gel filtration analysis revealed that API5 and caspase-2 are shifting towards high molecular weight fractions in PFT-treated cells (Fig. 1c) . Together, these results confirmed that API5 is probably associated directly with the activation of caspase-2. We then explored if API5 plays a role in the regulation of cell death mediated by PFTs. Immunoblot analysis of PFT-treated cells revealed that API5 tends to be degraded in apoptotic cells (Fig. 2a) .
To decipher the physiological role of API5 in regulating caspase-2 activation, we resorted to both siRNA and shRNA-mediated loss of function approaches. As expected, stable knockdown of API5 sensitized HeLa cells to PFT-mediated cell death ( Fig. 2b and 2c). These results are recapitulated with two different siRNAs targeting API5 ( Fig.   2d and Supplementary Fig. S1a and S1b). Consistently, enhanced PARP cleavage is detected in API5-depleted cells as early as 9 h post induction (Fig. 2d) . As expected, enhanced caspase-3/7 activity was detected in API5-depleted cells treated with PFT ( Supplementary Fig. S1c ). Long-term clonogenicity and cell survival assays with API5-specific shRNAs further confirmed that depletion of API5 significantly reduced the survival of PFT-treated HeLa cells (Figs. 2e-2g ). API5-depleted cells were sensitized to PFT but not to TNFα/CHX, staurosporine, camptothecin, etoposide, cisplatin and brefeldin A (Figs. 3a and 3b) . To avoid any cell type-specific phenotypes, we performed similar experiments in NCI-H1650 lung carcinoma cell lines. Depletion of API5 strongly sensitized these cells to PFT-but not to TNFα/CHX-, camptothecin-or etoposide-induced cell death ( Supplementary Fig. S2a-c) . We then tested whether API5 directly influences caspase-2 activation in vivo. Caspase-2 possesses a CARD domain at its N-terminus and CARD-mediated dimerization is required for its initial activation [21, 22] . This initial activation step is followed by auto-processing leading to a mature caspase-2 dimer containing two P19 and P12 subunits [7] . We tested whether caspase-2 dimerization and/or activation are enhanced in response to PFTs in API5-depleted cells by employing the "in situ active caspase trapping" approach [22, 23] . As expected, experiments employing biotin-VAD revealed that more active, dimerized caspase-2 was detected in API5-depleted cells after PFT treatment (Fig. 4a ). Caspase-2 activity assays employing a fluorogenic substrate (VDVAD-AFC) also confirmed increased caspase-2 activation in API5-depleted cells in response to PFTs (Supplementary Fig. S3a ).
Further, we also detected enhanced caspase-2 processing in response to PFT in API5-depleted cells (Fig. 3a, 4b and Supplementary Fig. S3b ). As caspase-2 processing can also happen downstream of effector caspase activation [24] , we have reconfirmed whether caspase-2 activation is triggered in the absence of caspase-3/7 in response to depletion of potassium ions as with PFTs [25] . To perform these experiments, we have employed valinomycin as MEFs are unresponsive to α-toxin. As expected, caspase-2 activity was triggered in Caspase3/7 double knockout MEFs in response to valinomycin ( Supplementary Fig. S4 ).
We then tested if the sensitization to cell death observed in API5-depleted cells is dependent on caspase-2. Consistently, co-knockdown of caspase-2 reduced the sensitization to apoptosis in API5-depleted cells suggesting a role for API5 in inhibiting caspase-2-mediated cell death (Figs. 4c and 4d ). In addition, we explored the potential mechanisms by which API5 can regulate caspase-2 dimerization. As API5 possesses HEAT repeats and ARM-like repeats, we tested if API5 can directly interact with caspase-2. Flag pulldown experiments employing recombinant API5 and in vitrotranslated caspase-2 produced from rabbit reticulocyte lysates revealed a direct interaction between API5 and caspase-2 (Fig. 5a) . Interestingly, deletion of 50 amino acids at the C-terminus of API5 (API5 1-454=API5ΔC) abrogated this interaction (Fig.   5a ). As API5 directly binds to caspase-2 and regulates caspase-2 dimerization, we hypothesized that API5 can directly bind to the CARD domain, which is responsible for driving this dimerization event. In vitro binding experiments, employing recombinant proteins confirmed a direct interaction between the CARD domain of caspase-2 and API5 (Fig. 5b) . As expected, API5ΔC failed to interact with the CARD domain of caspase-2. As CARD domains are also present in other caspases like caspase-9 and
caspase-1, we tested if API5 can bind to them. Interestingly, we failed to detect any interaction between API5 in caspase-9 or caspase-1 ( Supplementary Fig. S5a and S5b).
Consistently, loss of API5 failed to sensitize cells to caspase-9-dependent cell death (Fig. 3b ). Next, we tested if recombinant API5 can directly inhibit the activity of fully processed recombinant caspase-2, which is devoid of CARD domains. Incubation of increasing concentrations of API5 failed to inhibit the activity of fully processed caspase-2 ( Fig. 5c ). To further confirm the role of API5 in inhibiting dimerization of the CARD domains directly, we performed in vitro reconstitution experiments employing full-length caspase-2 purified from rabbit reticulocyte lysates. As expected, presence of API5 directly prevented the dimer formation between Flag-tagged caspase-2 and Histagged caspase-2 ( Fig. 5d ). To further confirm these observations, we have performed additional gain of function experiments. Consistently, overexpression of API5 inhibited the activity of co-expressed caspase-2 in a concentration-dependent manner (Fig. 5e ).
Taken together, these data suggest that API5 is a direct inhibitor of caspase-2 and that API5 directly binds and impedes CARD-mediated dimerization and activation (Fig. 5f ).
IAPs are known to inhibit caspases (casp-8/9 and casp-3/-7) directly through their BIR (Baculoviral IAP Repeat) domains and RING domains and direct inhibitors of caspase-2 are thus far unknown [26] . Caspase-2 was cloned in 1994 and despite intense research, the molecular machinery driving the activation of this caspase remains unclear [27, 28] .
Though the PIDDosome serves as an activation platform during DNA damage-mediated apoptosis, caspase-2 can also be activated in the absence of PIDD and RAIDD [10] . We have demonstrated that caspase-2 can be recruited to a high molecular weight complex in a PIDD-or RAIDD-independent manner in response to PFTs in human epithelial cells [11] . Here, by employing mass spectrometry, we identified API5 as a novel inhibitor of caspase-2. While cleavage is essential for effector caspase activation, initiator caspases depend on dimerization of caspase monomers but not on cleavage for activation [5] . Initiator caspases are brought to close proximity in multimeric protein complexes leading to their activation and auto-processing. CARD domain-containing proteins exhibit homophilic interactions with other CARD domain-carrying proteins leading to the formation of high order multimers in cells [29] . Thus, binding of CARD domain-containing caspases with adaptor molecules like RAIDD or APAF1 leads to an increased local concentration of the initiator caspases resulting in their dimerization and activation. Here, we present one of the first inhibitors of caspases that directly interferes with the CARD-CARD interaction both in vitro and in vivo. Our in vitro binding experiments with recombinant proteins reveal that the C-terminus of API5 is required for interaction with the caspase-2 CARD domain. However, it is currently unclear if the C-terminal fragment drives the interaction or if the deletion of the API5 C-terminus leads to an altered conformation of API5 that fails to interact with CARD domains.
Interestingly, we could not detect any interaction with the CARD domain of caspase-9 or caspase-1. Thus, further biochemical and structural analyses are clearly warranted to characterize the interaction between API5 and caspase-2. API5 has also been shown to be upregulated in several cancers and our studies raise the possibility that inhibition of caspase-2 activation could possibly contribute to the pro-tumorigenic role of API5 and chemoresistance. Interestingly, API5 is degraded in apoptotic cells (Fig 2a and 3a) and further studies are warranted to uncover the mechanisms driving this degradation.
Further, caspase-2 was originally identified to contribute to growth factor deprivationinduced apoptosis, a process directly inhibited by API5 overexpression [30] . Our preliminary data suggest that loss of API5 also sensitizes tumour cells to starvationinduced cell death (GI and KR unpublished observations). However, it is currently unclear if caspase-2 is directly involved in this process. The role of caspase-2 in mediating DNA damage-or ER-stress-mediated apoptosis remains contentious and we detect that loss of API5 primarily sensitizes cells to PFT but not to other inducers of apoptosis ( Fig. 3 and Supplementary Fig. S2 ). API5 has also been shown to undergo phosphorylation and it would be interesting to explore if posttranslational modifications determine the binding of API5 to caspase-2 in cells [31] . Taken together, our study reveals a novel mechanism (direct disruption of CARD-mediated dimerization) regulating initiator caspase activation and identifies one of the first direct inhibitors of caspase-2. The study sheds further light on the mechanisms driving the activation of caspase-2, a poorly defined member of the caspase family.
Materials and methods

Cell culture and apoptosis induction
HeLa cells were cultured in RPMI-1640 medium and A549, NCI-H1650, Caspase-2 -/-and Caspase-3/7 DKO MEFs were cultured in DMEM (both Gibco BRL), both supplemented with 10% FCS (Gibco BRL), and 0.2% penicillin (100 U/ml) / streptomycin (100 µg/ml) (Gibco BRL) and 2 mM L-glutamine at 37 °C in 5% CO2.
The cell death experiments were performed with purified alpha-toxin (α-haemolysin from Staphylococcus aureus) (Sigma) for various time points. Staurosporine (Cell Signaling), cisplatin (Uniklinik Mainz), etoposide (Sigma), camptothecin (Selleckchem), TNFα (R&Dsystems), cycloheximide (Sigma), brefeldin A (Selleckchem), valinomycin (Sigma).
shRNA-mediated RNA interference by lentiviral particles
In order to achieve a stable knockdown, HeLa cells were seeded in 96-well plate format at 40,000 cells/100 μl medium. The next day, the medium was changed to polybrene 
SiRNA transfection
Cells were seeded into 12-well plates to obtain 50-60% confluency the next day.
Lipofectamine RNAimax (Invitrogen) transfection reagent was used to achieve efficient siRNA transfection (final DNA concentration: 60 nM). The next day, the medium was changed and cells were treated with α-toxin. Approximately a day later, the transfected samples were subjected to various treatments (like apoptosis induction) as specified in the figure legends. The following siRNAs provided efficient knockdowns: siAPI5#1 (SI02225580, QIAGEN), siAPI5#4 (Hs02_00341902, SIGMA).
Cell death assays
After the respective treatments, the cells (0. 
Biotin-VAD pull-down of activated caspases
HeLa cells were seeded into 6-well plates and were grown until 80-90% confluency. were centrifuged (2,300 rpm for 3 min at 4 o C) and the supernatant was thoroughly discarded. The beads were resuspended in 500 µl of KPM buffer. This step was repeated three times. Finally, the beads were resuspended in 60 µl of 5X Laemmli buffer with 5% beta-mercaptoethanol, were boiled and subjected to SDS-PAGE for subsequent immunoblot or mass spectrometric analysis. The mass spectrometry analysis was essentially performed as described earlier [11] .
Immunoblot analysis
Cells were lysed directly in 5X Laemmli (with 5% beta-mercaptoethanol) buffer and the proteins were separated by SDS-PAGE. The proteins were transferred to nitrocellulose membranes (90 min, 860 mA, RT) and the presence of proteins was monitored by immunoblot analysis following standard procedures. The following primary antibodies were employed: anti-caspase-2 (clone 11B4, Alexis), anti-API5, anti-Caspase-9, anti-PARP, anti-His (Cell Signaling Technologies) and anti-Actin (Sigma).
Fluorescence time-lapse microscopy
HeLa cells were plated into 12-well plates. Immediately after treatment, the cells were stained with either Caspase 3/7 reagent (Essen Bioscience), alternatively with YOYO-1
(Life Technologies) and Magic Red Caspase-3/7 Detection Kit (Immunochemistry
Technologies) following the manufacturer's instructions. The plates were incubated in the IncuCyte Zoom automated microscopy system (Essen BioScience), which enabled us to conduct the measurements inside a cell culture incubator (37°C, 5% CO2) in order to ensure stable conditions for long term measurements. Images were taken with a digital camera attached to the microscope at various time points (green channel:
Caspase-3/7 and YOYO-1; red channel: Magic Red Caspase-3/7; phase contrast channel) with 10x objective.
In vitro translation
In vitro translation assays were performed using the TNT Coupled Reticulocyte Lysate for 90 minutes and subsequently frozen at -80°C.
In vitro pulldown experiments
The DNA encoding the CARD domain (amino acid 15-104) of human caspase-2was amplified with PCR and cloned into pGEX4T vector (GE Healthcare) using BamHI and by FLAG beads and the interaction with API5 is tested with recombinant API5 proteins as described above.
Caspase-9 immunoprecipitation
Hela cells were harvested at 80% confluency (2 wells of a 6-well plate/sample) and resuspended in 500 μl RIPA buffer (50 mM Tris HCl, pH 7.5, 250 mM NaCl, 10%
Glycerol, 1% Triton X-100 with protease inhibitor cocktail (ROCHE) and 1 mM DTT. 
Caspase-2 activity assay
Depending on the experiment, either 1x10 6 cells or purified recombinant proteins (human recombinant caspase-2 (ENZO) with human recombinant API5) were resuspended in 50 μl ice cold lysis buffer and incubated on ice for 10 minutes. Next, 50 μl 2x Reaction buffer (with freshly added DTT, 1mM) was pipetted and finally 5 μl of caspase-2 fluorometric caspase substrate (VDVAD-AFC, final concentration 50 μM)
was mixed with the sample (Caspase-2 Fuorometric assay kit, ENZO). The mixtures were incubated in a flat bottom 96-well plate at 37 °C for various time points and the fluorescence intensity increase was detected using a Fluorometric Plate Reader (Victor X, Perkin Elmer).
Size exclusion chromatography from endogenous samples
HeLa cells (10x75 cm 2 flasks at 80% confluency) were treated with α-toxin and harvested by scraping at 4 hours post treatment. The control and treated samples were resuspended in hypotonic buffer and lysed by repeated freeze-thaw cycles (3x). Next, the lysates were centrifuged and the supernatant was collected in a separate tube. The samples were kept at 4°C and were subjected to size exclusion chromatography (column: sephacryl HR500 (GE)). The entire protocol was described previously [11] .
Statistical analysis
Student's t-test was performed to test for statistical significance of the results (*P=0.05, **P=0.01, ***P=0.005). The sample size (number of experiments) has been indicated in the figure as n.
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Figure legends
Magnetic beads were washed 5 times and then incubated overnight at 4°C with recombinant API5. After washing (3X) the beads were re-suspended in SDS buffer and subjected to western blot analysis.
